IRTC Quote, Financials, Valuation and Earnings

Masimo has a net margin of -0.81% compared to iRhythm Technologies's net margin of -58.2%. iRhythm Technologies's return on equity of -100.75% beat Masimo's return on equity of -23.05%.

iRhythm Technologies has a consensus price target of $130.92, signalling upside risk potential of 23.52%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 19.52%. Given that iRhythm Technologies has higher upside potential than Masimo, analysts believe iRhythm Technologies is more attractive than Masimo.

iRhythm Technologies has a beta of 1.450, which suggesting that the stock is 44.979% more volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $164.3M, which are smaller than Masimo quarterly revenues of $600.7M. iRhythm Technologies's net income of -$1.3M is higher than Masimo's net income of -$349.6M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.59x versus 4.23x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of -0.81% compared to iRhythm Technologies's net margin of -87.01%. iRhythm Technologies's return on equity of -100.75% beat Outset Medical's return on equity of -178.08%.

iRhythm Technologies has a consensus price target of $130.92, signalling upside risk potential of 23.52%. On the other hand Outset Medical has an analysts' consensus of $21.75 which suggests that it could grow by 87.82%. Given that Outset Medical has higher upside potential than iRhythm Technologies, analysts believe Outset Medical is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.450, which suggesting that the stock is 44.979% more volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $164.3M, which are larger than Outset Medical quarterly revenues of $29.5M. iRhythm Technologies's net income of -$1.3M is higher than Outset Medical's net income of -$25.6M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.59x versus 0.35x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -0.81% compared to iRhythm Technologies's net margin of 16.85%. iRhythm Technologies's return on equity of -100.75% beat Insulet's return on equity of 43.11%.

iRhythm Technologies has a consensus price target of $130.92, signalling upside risk potential of 23.52%. On the other hand Insulet has an analysts' consensus of $312.27 which suggests that it could grow by 19.78%. Given that iRhythm Technologies has higher upside potential than Insulet, analysts believe iRhythm Technologies is more attractive than Insulet.

iRhythm Technologies has a beta of 1.450, which suggesting that the stock is 44.979% more volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $164.3M, which are smaller than Insulet quarterly revenues of $597.5M. iRhythm Technologies's net income of -$1.3M is lower than Insulet's net income of $100.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Insulet's PE ratio is 45.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.59x versus 9.30x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -0.81% compared to iRhythm Technologies's net margin of 28.26%. iRhythm Technologies's return on equity of -100.75% beat ResMed's return on equity of 25.76%.

iRhythm Technologies has a consensus price target of $130.92, signalling upside risk potential of 23.52%. On the other hand ResMed has an analysts' consensus of $263.15 which suggests that it could grow by 11.56%. Given that iRhythm Technologies has higher upside potential than ResMed, analysts believe iRhythm Technologies is more attractive than ResMed.

iRhythm Technologies has a beta of 1.450, which suggesting that the stock is 44.979% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.88% to investors and pays a quarterly dividend of $0.53 per share. iRhythm Technologies pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iRhythm Technologies quarterly revenues are $164.3M, which are smaller than ResMed quarterly revenues of $1.3B. iRhythm Technologies's net income of -$1.3M is lower than ResMed's net income of $365M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while ResMed's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 5.59x versus 6.93x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.